Molecular alterations during insulinoma tumorigenesis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1775, Issue 2, 2007, Pages 313-332

  Jonkers, Y M H ^a   Ramaekers, F C S ^a   Speel, E J M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Candidate genes; Cell cycle; Chromosomal aberrations; EPT; Insulinoma; Progression markers

Indexed keywords

ANTINEOPLASTIC AGENT; DIAZOXIDE; METHIONINE; SOMATOSTATIN DERIVATIVE;

ANGIOGENESIS; APOPTOSIS; CANCER INVASION; CARCINOGENESIS; CELL LINE; CHROMOSOME ABERRATION; CLINICAL FEATURE; DISEASE MARKER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; INSULINOMA; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR CLASSIFICATION; TUMOR GROWTH;

GENETIC MARKERS; HUMANS; INSULINOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 34250173799     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2007.05.004     Document Type: Review

References (182)

1. Cowgill S.M., and Muscarella P. The genetics of pancreatic cancer. Am. J. Surg. 186 (2003) 279-286
2. Bardeesy N., and DePinho R.A. Pancreatic cancer biology and genetics. Nat. Rev., Cancer 2 (2002) 897-909
3. Tomassetti P., Campana D., Piscitelli L., Casadei R., Santini D., Nori F., Morselli-Labate A.M., Pezzilli R., and Corinaldesi R. Endocrine pancreatic tumors: factors correlated with survival. Ann. Oncol. 16 (2005) 1806-1810
4. Vortmeyer A.O., Huang S., Lubensky I., and Zhuang Z. Non-islet origin of pancreatic islet cell tumors. J. Clin. Endocrinol. Metab. 89 (2004) 1934-1938
5. Heitz P.U., Komminoth P., Perren A., Klimstra D.S., and Dayal Y. Tumours of the endocrine pancreas. In: DeLellis R.A., Lloyd R.V., Heitz P.U., and Eng C. (Eds). Pathology and Genetics. Tumours of endocrine organs (2004), IARC Press, Lyon 177-208
6. Dor Y., Brown J., Martinez O.I., and Melton D.A. Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429 (2004) 41-46
7. Perren A., Anlauf M., Henopp T., Rudolph T., Schmitt A., Raffel A., Gimm O., Weihe E., Knoefel W.T., Dralle H., Heitz P.U., Komminoth P., and Klöppel G. Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J. Clin. Endocrinol. Metab. 92 (2007) 1118-1128
8. Oberg K., and Eriksson B. Endocrine tumors of the pancreas. Best practice and research. Clin. Gastroenterol. 19 (2005) 753-781
9. Frankel W.L. Update on pancreatic endocrine tumors. Arch. Pathol. Lab. Med. 130 (2006) 963-966
10. Chung D.C., Smith A.P., Louis D.N., Graeme-Cook F., Warshaw A.L., and Arnold A.A. Novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J. Clin. Invest. 100 (1997) 404-410
11. Lubensky I.A., Pack S., Ault D., Vortmeyer A.O., Libutti S.K., Choyke P.L., Walther M.M., Linehan W.M., and Zhuang Z. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am. J. Pathol. 153 (1998) 223-231
12. Perren A., Komminoth P., and Heitz P.U. Molecular genetics of gastroenteropancreatic endocrine tumors. Ann. N. Y. Acad. Sci. 1014 (2004) 199-208
13. Stumpf E., Aalto Y., Hoog A., Kjellman M., Otonkoski T., Knuutila S., and Andersson L.C. Chromosomal alterations in human pancreatic endocrine tumors. Genes Chromosomes Cancer 28 (2000) 83-87
14. Speel E.J.M., Richter J., Moch H., Egenter C., Saremaslani P., Rutimann K., Zhao J., Barghorn A., Roth J., Heitz P.U., and Komminoth P. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am. J. Pathol. 155 (1999) 1787-1794
15. Speel E.J.M., Scheidweiler A.F., Zhao J., Matter C., Saremaslani P., Roth J., Heitz P.U., and Komminoth P. Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9q34 is an early event in insulinomas. Cancer Res. 61 (2001) 5186-5192
16. Zhao J., Moch H., Scheidweiler A.F., Baer A., Schäffer A.A., Speel E.J.M., Roth J., Heitz P.U., and Komminoth P. Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer 32 (2001) 364-372
17. Ebrahimi S.A., Wang E.H., Wu A., Schreck R.R., Passaro Jr. E., and Sawicki M.P. Deletion of chromosome 1 predicts prognosis in pancreatic endocrine tumors. Cancer Res. 59 (1999) 311-315
18. Rigaud G., Missiaglia E., Moore P.S., Zamboni G., Falconi M., Talamini G., Pesci A., Baron A., Lissandrini D., Rindi G., Grigolato P., Pederzoli P., and Scarpa A. High resolution allelotype of non-functional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res. 61 (2001) 285-292
19. Barghorn A., Komminoth P., Bachmann D., Rütimann K., Saremaslani P., Mulatta-Feurer S., Perren A., Roth J., Heitz P.U., and Speel E.J. Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. J. Pathol. 94 (2001) 451-458
20. Hessman O., Lindberg D., Einarsson A., Lillhager P., Carling T., Grimelius L., Eriksson B., Akerstrom G., Westin G., and Skogseid B. Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN1-associated pancreatic endocrine tumors. Genes Chromosomes Cancer 26 (1999) 258-264
21. Moore P.S., Missiaglia E., Antonello D., Zamo A., Zamboni G., Corleto V., Falconi M., and Scarpa A. Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes Chromosomes Cancer 32 (2001) 177-181
22. Barghorn A., Speel E.J.M., Farspour B., Saremaslani P., Schmid S., Perren A., Roth J., Heitz P.U., and Komminoth P. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am. J. Pathol. 158 (2001) 1903-1911
23. Moore P.S., Orlandini S., Zamboni G., Capelli P., Rigaud G., Falconi M., Bassi C., Lemoine N.R., and Scarpa A. Pancreatic tumors: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br. J. Cancer 84 (2001) 253-262
24. Serrano J., Goebel S.U., Peghini P.L., Lubensky I.A., Gibril F., and Jensen R.T. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J. Clin. Endocrinol. Metab. 85 (2000) 4146-4156
25. Perren A., Komminoth P., Saremaslani P., Matter C., Feurer S., Lees J.A., Heitz P.U., and Eng C. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol. 157 (2000) 1097-1103
26. Cupisti K., Hoppner W., Dotzenrath C., Simon D., Berndt I., Roher H.D., and Goretzki P.E. Lack of MEN1 gene mutations in 27 sporadic insulinomas. Eur. J. Clin. Invest. 30 (2000) 325-329
27. Gortz B., Roth J., Krahenmann A., de Krijger R.R., Muletta-Feurer S., Rutimann K., Saremaslani P., Speel E.J., Heitz P.U., and Komminoth P. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am. J. Pathol. 154 (1999) 429-436
28. Hessman O., Lindberg D., Skogseid B., Carling T., Hellman P., Rastad J., Akerstrom G., and Westin G. Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas. Cancer Res. 58 (1998) 377-379
29. Perren A., Barghorn A., Schmid S., Saremaslani P., Roth J., Heitz P.U., and Komminoth P. Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients. Oncogene 21 (2002) 7605-7608
30. Shattuck T.M., Costa J., Bernstein M., Jensen R.T., Chung D.C., and Arnold A. Mutational analysis of Smad3, a candidate tumor suppressor implicated in TGF-beta and menin pathways, in parathyroid adenomas and enteropancreatic endocrine tumors. J. Clin. Endocrinol. Metab. 87 (2002) 3911-3914
31. Perren A., Hurlimann S., Saremaslani P., Schmid S., Bonvin C., Roth J., Heitz P.U., and Komminoth P. DPC4/Smad4 expression is lost in a subset of ductal adenocarcinomas of the pancreas but not in endocrine pancreatic tumors and chronic pancreatitis. Mod. Pathol. 15 (2002) 119A
32. Wild A., Langer P., Celik I., Chaloupka B., and Bartsch D.K. Chromosome 22q in pancreatic endocrine tumors: identification of a homozygous deletion and potential prognostic associations of allelic deletions. Eur. J. Endocrinol. 147 (2002) 507-513
33. Missiaglia E., Moore P.S., Williamson J., Lemoine N.R., Falconi M., Zamboni G., and Scarpa A. Sex chromosome anomalies in pancreatic endocrine tumors. Int. J. Cancer 98 (2002) 532-538
34. Danforth D.N., Gorden P., and Brennan M.F. Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery 96 (1984) 1027-1037
35. Anlauf M., Wieben D., Perren A., Sipos B., Komminoth P., Raffel A., Kruse M.L., Fottner C., Knoefel W.T., Monig H., Heitz P.U., and Kloppel G. Persistent hyperinsulinemic hypoglycaemia in 15 adults with diffuse nesidioblastosis. Am. J. Surg. Pathol. 29 (2005) 524-533
36. Service F.J., Natt N., Thompson G.B., Grant C.S., van Heerden J.A., Andrews J.C., Lorenz E., Terzic A., and Lloyd R.V. Noninsulinoma pancreatogenous hypoglycaemia in adults independent of mutations in Kir6.2 and SUR1 genes. J. Clin. Endocrinol. Metab. 84 (1999) 1582-1589
37. Starke A., Saddig C., Kirch B., Tschahargane C., and Goretzki P. Islet hyperplasia in adults: challenge to preoperatively diagnose non-insulinoma pancreatogenic hypoglycaemia syndrome. World J. Surg. 30 (2006) 1-10
38. Lamberts S.W., Krenning E.P., and Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 12 (1991) 450-482
39. Tucker O.N., Crotty P.L., and Conlon K.C. The management of insulinoma. Br. J. Surg. 93 (2006) 264-275
40. Böttger T.C., Weber W., Beyer J., and Junginger T. Value of tumor localization in patients with insulinoma. World J. Surg. 14 (1990) 107-112
41. Toniato A., Meduri F., Foletto M., Avogaro A., and Pelizzo M. Laparoscopic treatment of benign insulinomas localized in the body and tail of the pancreas: a single-center experience. World J. Surg. 30 (2006) 1916-1919
42. McAuley G., Delaney H., Colville J., Lyburn I., Worsley D., Govender P., and Torreggiani W.C. Multimodality preoperative imaging of pancreatic insulinomas. Clin. Radiol. 60 (2005) 1039-1050
43. Williams A.J., Coates P.J., Lowe D.G., McLean C., and Gale E.A. Immunochemical investigation of insulinomas for islet amyloid polypeptide and insulin: evidence for differential synthesis and storage. Histopathology 21 (1992) 215-223
44. Wolf E.L., Sprayregen S., Frager D., Rifkin H., and Gliedman M.L. Calcification in an insulinoma of the pancreas. Am. J. Gastroenterol. 79 (1984) 559-561
45. Illyes G., Bucsek M.J., Kadar A., Horanyi J., and Flautner L. Ultrastructural study of a black insulinoma. Ultrastruct. Pathol. 17 (1993) 495-501
46. Komminoth P., Heitz P.U., and Roth J. Human insulinoma: clinical, cellular, and molecular aspects. Endocr. Pathol. 10 (1999) 269-281
47. Roth J., Kloppel G., Madsen O.D., Storch M.J., and Heitz P.U. Distribution patterns of proinsulin and insulin in human insulinomas: an immunohistochemical analysis in 76 tumors. Virchows Arch. 63 (1992) 51-61
48. Akerstrom G., and Hellman P. Surgery on neuroendocrine tumors. Best Pract. Res. Clin. Endocrinol. Metab. 21 (2007) 87-109
49. de Herder W.W. Insulinoma. Neuroendocrinology 80 (2004) 20-22
50. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
51. Jonkers Y.M.H., Claessen S.M.H., Perren A., Schmid S., Komminoth P., Verhofstad A.A., Hofland L.J., de Krijger R.R., Slootweg P.J., Ramaekers F.C.S., and Speel E.J.M. Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr. Relat. Cancer 12 (2005) 435-447
52. Jonkers Y.M.H., Claessen S.M.H., Feuth T., Geurts van Kessel A., Ramaekers F.C.S., Veltman J.A., and Speel E.J.M. Novel candidate tumor suppressor gene loci on chromosomes 11q23-24 and 22q13 involved in human insulinoma tumorigenesis. J. Pathol. 210 (2006) 450-458
53. Jonkers Y.M.H., Claessen S.M.H., Veltman J.A., Geurts van Kessel A., Dinjens W.N.M., Skogseid B., Ramaekers F.C.S., and Speel E.J.M. Molecular parameters associated with insulinoma progression: chromosomal instability versus p53 and CK19 status. Cytogenet. Genome Res. 115 (2006) 289-297
54. Pavelic K., Hrascan R., Kapitanovic S., Karapandza N., Vranes Z., Belicza M., Kruslin B., and Cabrijan T. Multiple genetic alterations in malignant metastatic insulinomas. J. Pathol. 177 (1995) 395-400
55. Schnepp R.W., Hou Z., Wang H., Petersen C., Silva A., Masai H., and Hua X. Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Res. 64 (2004) 6791-6796
56. Karnik S.K., Hughes C.M., Gu X., Rozenblatt-Rosen O., McLean G.W., Xiong Y., Meyerson M., and Kim S.K. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27KIP1 and p18INK4C. Proc. Natl. Acad. Sci. 102 (2005) 14659-14664
57. Schnepp R.W., Chen Y.X., Wang H., Cash T., Silva A., Diehl J.A., Brown E., and Hua X. Mutation of tumor suppressor gene MEN1 acutely enhances proliferation of pancreatic islet cells. Cancer Res. 66 (2006) 5707-5715
58. Canavese G., Azzoni C., Pizzi S., Corleto V., Pasquali C., Davoli C., Crafa P., Delle Fave G., and Bordi C. p27: A potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behaviour. Human Pathol. 32 (2001) 1094-1101
59. Tomita T. Cyclin-dependent kinase (cdk6) and p16 in pancreatic endocrine neoplasms. Pathology 36 (2004) 566-570
60. Bartch D.K., Kersting M., Wild A., Ramaswamy A., Gerdes B., Schuermann M., Simon B., and Rothmund M. Low frequency of p16 (INK4a) alterations in insulinomas. Digestion 62 (2000) 171-177
61. Lubomierski N., Kersting M., Bert T., Muench K., Wulbrand U., Schuermann M., Bartsch D., and Simon B. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors. Cancer Res. 61 (2001) 5905-5910
62. Stalberg P., Grimfjard P., Santesson M., Zhou Y., Lindberg D., Gobl A., Oberg K., Westin G., Rastad J., Wang S., and Skogseid B. Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, (-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J. Clin. Endocrinol. Metab. 89 (2004) 2326-2337
63. Chung D.C., Brown S.B., Graeme-Cook F., Seto M., Warshaw A.L., Jensen R.T., and Arnold A. Overexpression of cyclin D1 occurs frequently in human pancreatic endocrine tumors. J. Clin. Endocrinol. Metab. 85 (2000) 4373-4378
64. Guo S.S., Wu X., Shimoide A.T., Wong J., Moatamed F., and Sawicki M.P. Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumors. J. Endocrinol. 179 (2003) 73-79
65. Fatrai S., Elghazi L., Balcazar N., Cras-Meneur C., Krits I., Kiyokawa H., and Bernal-Mizrachi E. Akt induces β-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity. Diabetes 55 (2006) 318-325
66. Wang X.C., Xu S.Y., Wu X.Y., Song H.D., Mao Y.F., Fan H.Y., Yu F., Mou B., Gu Y.Y., Xu L.Q., Zhou X.O., Chen Z., Chen J.L., and Hu R.M. Gene expression profiling in human insulinoma tissue: genes involved in the insulin secretion pathway and cloning of novel full-length cDNAs. Endocr. Relat. Cancer 11 (2004) 295-303
67. Korc M., and Finman J.E. Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-alpha. J. Biol. Chem. 264 (1989) 14990-14999
68. Hsieh E.T., Shepherd F.A., and Tsao M.S. Co-expression of epidermal growth factor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma. Lung Cancer 29 (2000) 151-157
69. DeAizpurua H.J., Cram D.S., Naselli G., Devereux L., and Dorow D.S. Expression of mixed lineage kinase-1 in pancreatic β-cell lines at different stages of maturation and during embryonic pancreas development. J. Biol. Chem. 272 (1997) 16364-16373
70. Davoren P.M., and Epstein M.T. Insulinoma complicating tuberous sclerosis. J. Neurol. Neurosurg. Psychiatry 55 (1992) 1209
71. Balogh K., Racz K., Patocs A., and Hunyadi L. Menin and its interacting proteins: elucidation of menin function. Trends Endocrinol. Metab. 17 (2006) 357-364
72. Iwamura Y., Futagawa T., Kaneko M., Nahagawa K., Kawai K., Yamashita K., Nakamura T., and Hayashi H. Co-deletions of the retinoblastoma gene and Wilms' tumor gene and rearrangement of the Krev-1 gene in a human insulinoma. Jpn. J. Clin. Oncol. 22 (1992) 6-9
73. Chung D.C., Smith A.P., Louis D.N., Graeme-Cook F., Warshaw A.L., and Arnold A. Analysis of the retinoblastoma tumor suppressor gene in pancreatic endocrine tumors. Clin. Endocrinol. 47 (1997) 523-528
74. Harvey M., Vogel H., Lee E.Y.H.P., Bradley A., and Donehower L.A. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res. 55 (1995) 1146-1151
75. Nguyen K.T.T., Tajmir P., Lin C.H., Liadis N., Zhu X.D., Eweida M., Tolasa-Karaman G., Cai F., Wang R., Kitamura T., Belsham D.D., Wheeler M.B., Suzuki A., Mak T.W., and Woo M. Essential role of PTEN in body size determination and pancreatic β-cell homeostasis in vivo. Mol. Cell. Biol. 26 (2006) 4511-4518
76. Zhang L., Fu Z., Binkley C., Giordano T., Burant C.F., Logsdon C.D., and Simeone D.M. Raf kinase inhibitory protein inhibits β-cell proliferation. Surgery 136 (2004) 708-715
77. Zhuang Z., Vortmeyer A.O., Pack S., Huang S., Pham T.A., Wang C., Park W.S., Agarwal S.K., Debelenko L.V., Kester M., Guru S.C., Manickam P., Olufemi S.E., Yu F., Heppner C., Crabtree J.S., Skarulis M.C., Venzon D.J., Emmert-Buck M.R., Spiegel A.M., Chandrasekharappa S.C., Collins F.S., Burns A.L., Marx S.J., Jensen R.T., Liotta L.A., and Lubensky I.A. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res. 57 (1997) 4682-4686
78. Moore P.S., Beghelli S., Zamboni G., and Scarpa A. Genetic abnormalities in pancreatic cancer. Mol. Cancer 2 (2003) 7-12
79. Bertolino P., Tong W.M., Herrera P.L., Casse H., Zhang C.X., and Wang Z.Q. Pancreatic β-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Res. 63 (2003) 4836-4841
80. Crabtree J.S., Scacheri P.C., Ward J.M., McNally S.R., Swain G.P., Montagna C., Hager J.H., Hanahan D., Edlund H., Magnuson M.A., Garrett-Beal L., Burns A.L., Ried T., Chandrasekharappa S.C., Marx S.J., Spiegel A.M., and Collins F.S. Of mice and MEN1: insulinomas in a conditional mouse knockout. Mol. Cell. Biol. 23 (2003) 6075-6085
81. Lee C.S. Lack of p53 immunoreactivity in pancreatic endocrine tumors. Pathology 28 (1996) 139-141
82. Jin S., Mao H., Schnepp R.W., Sykes S.M., Silva A.C., D'Andrea A.D., and Hua X. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res. 63 (2003) 4204-4210
83. Wang D.G., Johnston C.F., and Buchanan K.D. Oncogene expression in gastroenteropancreatic neuroendocrine tumors. Implications for pathogenesis. Cancer 80 (1997) 668-675
84. Broustas C.G., Gokhale P.C., Rahman A., Dritschilo A., Ahmad I., and Kasid U. BRCC2, a novel BH3-like domain-containing protein, induces apoptosis in a caspase-dependent manner. J. Biol. Chem. 279 (2004) 26780-26788
85. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F., and Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
86. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., and Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 (1990) 334-336
87. Grabowski P., Griss S., Arnold C.N., Horsch D., Goke R., Arnold R., Heine B., Stein H., Zeitz M., and Scherubl H. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. Neuroendocrinology 81 (2005) 1-9
88. Wang Z., Zhang Y., Li Y., Banerjee S., Liao J., and Sarkar F.H. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. 5 (2006) 483-493
89. Heppner C., Bilimoria K.Y., Agarwal S.K., Kester M., Whitty L.J., Guru S.C., Chandrasekharappa S.C., Collins F.S., Spiegel A.M., Marx S.J., and Burns A.L. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 20 (2001) 4917-4925
90. Lin S.Y., and Elledge S.J. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113 (2003) 881-889
91. Kallioniemi A., Kallioniemi O.P., Sudar D., Rutovitz D., Gray J.W., Waldman F., and Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258 (1992) 818-821
92. Davies J.J., Wilson I.M., and Lam W.L. Array CGH technologies and their applications to cancer genomes. Chromosome Res. 13 (2005) 237-248
93. Pinkel D., and Albertson D.G. Array comparative genomic hybridization and its applications in cancer. Nat. Genet. 37 (2005) 11-17
94. Gumbs A.A., Moore P.S., Falconi M., Bassi C., Beghelli S., Modlin I., and Scarpa A. Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. J. Surg. Oncol. 81 (2002) 45-53
95. Chan A.O., Kim S.G., Bedeir A., Issa J.P., Hamilton S.R., and Rashid A. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22 (2003) 924-934
96. Chandrasekharappa S.C., and The B.T. Functional studies of the MEN1 gene. J. Int. Med. 253 (2003) 606-615
97. Tomassetti P., Cometa G., Del Vecchio E., Baserga M., Faccioli P., Bosoni D., Paolucci G., and Barbara L. Chromosomal instability in multiple endocrine neoplasia type 1. Cancer Genet. Cytogenet. 79 (1995) 123-126
98. Hessman O., Skogseid B., Westin G., and Akerstrom G. Multiple allelic deletions and intratumoral genetic heterogeneity in MEN1 pancreatic tumors. J. Clin. Endocrinol. Metab. 86 (2001) 1355-1361
99. Franklin D.S., Godfrey V.L., O'Brien D.A., Deng C., and Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol. Cell. Biol. 20 (2000) 6147-6158
100. Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., Samson E., Bink K., Hofler H., Fend F., Graw J., and Atkinson M.J. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. 103 (2006) 15558-15563
101. Liu L., Broaddus R.R., Yao J.C., Xie S.S., White J.A., Wu T.T., Hamilton S.R., and Rashid A. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod. Pathol. 18 (2005) 1632-1640
102. Sotillo R., Dubus P., Martin J., dela Cueva E., Ortega S., Malumbres M., and Barbacid M. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 20 (2001) 6637-6647
103. Vax V.V., Bibi R., Diaz-Cano S., Gueorguiev M., Kola B., Borboli N., Bressac-de Paillerets B., Walker G.J., Dedov I.I., Grossman A.B., and Korbonits M. Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumors. J. Endocrinol. 178 (2003) 301-310
104. Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L., Franklin R.A., and McCubrey J.A. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17 (2003) 590-603
105. Wulbrand U., Remmert G., Zofel P., Wied M., Arnold R., and Fehmann H.C. mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumors. Eur. J. Clin. Invest. 30 (2000) 729-739
106. von Wichert G., Jehle P.M., Hoeflich A., Koschnick S., Dralle H., Wolf E., Wiedenmann B., Boehm B.O., Adler G., and Seufferlein T. Insulin-like growth factor-1 is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 60 (2000) 4573-4581
107. La P., Schnepp R.W., Petersen C.D., Silva A.C., and Hua X. Tumor suppressor menin regulates expression of insulin-like growth factor binding protein 2. Endocrinology 145 (2004) 3443-3450
108. Granata R., Settani F., Biancone L., Trovato L., Nano R., Bertuzzi F., Destefanis S., Annunziata M., Martinetti M., Catapano F., Ghe C., Isgaard J., Papotti M., Ghigo E., and Muccioli G. Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic β cells and human islets. Involvement of cAMP/PKA, ERK1/2 and PI3K/AKT signalling. Endocrinology 148 (2007) 512-529
109. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
110. Tomasetto C., Karam S.M., Ribieras S., Masson R., Lefebvre O., Staub A., Alexander G., Chenard M.P., and Rio M.C. Identification and characterization of a novel gastric peptide hormone: the motilin-related peptide. Gastroenterology 119 (2000) 395-405
111. Prado C.L., Pugh-Bernard A.E., Elghazi L., Sosa-Pineda B., and Sussel L. Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2924-2929
112. Ekeblad S., Lejonklou M.H., Grimfjard P., Johansson T., Eriksson B., Grimelius L., Stridsberg M., Stalberg P., and Skogseid B. Co-expression of ghrelin and its receptor in pancreatic endocrine tumors. Clin. Endocrinol. 66 (2007) 115-122
113. Volante M., Allia E., Gugliotta P., Funaro A., Broglio F., Deghenghi R., Muccioli G., Ghigo E., and Papotti M. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J. Clin. Endocrinol. Metab. 87 (2002) 1300-1308
114. Schrader J., Arnold R., and Horsch D. The Rap1/B-Raf signalling complex is a putative therapeutic target in neuroendocrine tumors of the digestive tract. Neuroendocrinology 83 (2006) 57 (abstract B10)
115. Burns C.I., Squires P.E., and Persuad S.I. Signaling through the p38 and p42/44 mitogen-activated families of protein kinases in pancreatic β cell proliferation. Biochem. Biophys. Res. Commun. 268 (2000) 541-546
116. Tanabe K., Okuya S., Tanizawa Y., Matsutani A., and Oka Y. Leptin induces proliferation of pancreatic cell line MIN6 through activation of mitogen-activated protein kinase. Biochem. Biophys. Res. Commun. 241 (1997) 765-768
117. Yoshimoto K., Iwahana H., Fukuda A., Sano T., Katsuragi K., Kinoshita M., Saito S., and Itakura M. Ras mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Jpn. J. Cancer Res. 83 (1992) 1057-1062
118. Yashiro T., Fulton N., Hara H., Yasudo K., Montag A., Yashiro N., Straus II F., Ito K., Aiyoshi Y., and Kaplan E.L. Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery 114 (1993) 758-763
119. Perren A., Schmid S., Locher T., Saremaslani P., Bonvin C., Heitz P.U., and Komminoth P. BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr. Relat. Cancer 11 (2004) 855-860
120. Tannapfel A., Vomschloss S., Karhoff D., Markwarth A., Hengge U.R., Wittekind C., Arnold R., and Horsch D. BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. Am. J. Clin. Pathol. 123 (2005) 256-260
121. Landis C.A., Masters S.B., Spada A., Pace A.M., Bourne H.R., and Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumors. Nature 340 (1989) 692-696
122. Lyons J., Landis C.A., Harsh G., Vallar L., Grunewald K., Feichtinger H., Duh Q.Y., Clark O.H., Kawasaki E., Bourne H.R., et al. Two G protein oncogenes in human endocrine tumors. Science 249 (1990) 655-659
123. Suarez H.G., Duvillard J.A., Caillu B., Schlumberger M., Parmentier C., and Monier R. Gsp mutations in human thyroid tumors. Oncogene 6 (1991) 677-679
124. Vessey S.J.R., Jones P.M., Wallis S.C., Schofield J., and Bloom S.R. Absence of mutations in the Gsα Gi2α genes in sporadic parathyroid adenomas and insulinomas. Clin. Sci. 87 (1994) 493-497
125. Zeiger M.A., and Norton J.A. Gs alpha-identification of a gene highly expressed by insulinoma and other endocrine tumors. Surgery 114 (1993) 458-463
126. Pavelic K., Hrascan R., Kapitanovic S., Vranes Z., Cabrijan T., Spaventi S., Korsic M., Krizanac S., Li Y.Q., Stambrook P., Gluckman J.L., and Pavelic Z.P. Molecular genetics of malignant insulinoma. Anticancer Res. 16 (1996) 1707-1717
127. Papouchado B., Erickson L.A., Rohlinger A.L., Hobday T.J., Erlichman C., Ames M.M., and Lloyd R.V. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod. Pathol. 18 (2005) 1329-1335
128. Goldman J.M., and Melo J.V. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N. Engl. J. Med. 349 (2003) 1451-1464
129. DeGregory J. The Rb network. J. Cell Sci. 117 (2004) 3411-3413
130. Nagano K., Itagaki C., Izumi T., Nunomura K., Soda Y., Tani K., Takahashi N., Takenawa T., and Isobe T. Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase. Oncogene 25 (2006) 493-502
131. Muscarella P., Melvin W.S., Fisher W.E., Foor J., Ellison E.C., Herman J.G., Schirmer W.J., Hitchcock C.L., De Young B.R., and Weghorst C.M. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res. 58 (1998) 237-240
132. Cozar-Castellano I., Fiaschi-Taesch N., Bigatel T.A., Takane K.K., Garcia-Ocana A., Vasavada R., and Stewart A.F. Molecular control of cell cycle progression in the pancreatic β-cell. Endocr. Rev. 27 (2006) 356-370
133. Schmitt A.M., Anlauf M., Rousson V., Schmid S., Kofler A., Riniker F., Bauersfeld J., Barghorn A., Probst N., Moch H., Heitz P.U., Kloppel G., Komminoth P., and Perren A. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am. J. Surg. Pathol. (2007) in press
134. Fontaniere S., Casse H., Bertolino P., and Zhang C.X. Analysis of p27KIP1 expression in insulinomas developed in pancreatic β-cell specific MEN1 mutant mice. Familial Cancer 5 (2006) 49-54
135. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski P.P., and Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 (1998) 29-39
136. Pelengaris S., and Khan M. Oncogenic co-operation in β-cell tumorigenesis. Endocr. Relat. Cancer 8 (2001) 307-314
137. Miyashita T., and Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80 (1995) 293-299
138. Owen-Schaub L.B., Zhang W., and Cusack J.C. Wild-type p53 and a temperature-sensitive mutant induce Fas/Apo-1 expression. Mol. Cell. Biol. 15 (1995) 3032-3040
139. Hermeking H., and Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 265 (1994) 2091-2093
140. Guo S.S., Wu A.Y., and Sawicki M.P. Deletion of chromosome 1, but not mutation of MEN1 predicts prognosis in sporadic pancreatic endocrine tumors. World J. Surg. 26 (2002) 843-847
141. Bryan T.M., and Cech T.R. Telomerase and the maintenance of chromosome ends. Curr. Opin. Cell Biol. 11 (1999) 318-324
142. Tang S.J., Dumot J.A., Wang L., Memmesheimer C., Conwell D.L., Zuccaro G., Goormastic M., Ormsby A.H., and Cowell J. Telomerase activity in pancreatic endocrine tumors. Am. J. Gastroenterol. 97 (2002) 1022-1030
143. Lam K.Y., Lo C.Y., Fan S.T., and Luk J.M. Telomerase activity in pancreatic endocrine tumors: a potential marker for malignancy. Mol. Pathol. 53 (2000) 132-136
144. Marion-Audibert A.M., Barel C., Gouysse G., Dumortier J., Pilleul F., Pourreyron C., Hervieu V., Poncet G., Lombard-Bohas C., Chayvialle J.A., Partensky C., and Scoazec J.Y. Low microvessel density is an unfavourable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 125 (2003) 1094-1104
145. Couvelard A., O'Toole D., Turley H., Leek R., Sauvanet A., Degott C., Ruszniewski P., Belghiti J., Harris A.L., Gatter K., and Pezzella F. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumors: negative correlation of microvascular density and VEGF expression with tumor progression. Br. J. Cancer 92 (2005) 94-101
146. Schwarte-Waldhoff I., Volpert O.V., Bouck N.P., Sipos B., Hahn S.A., Klein-Scory S., Luttges J., Kloppel G., Graeven U., Eilert-Micus C., Hintelmann A., and Schmiegel W. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc. Natl. Acad. Sci. 97 (2000) 9624-9629
147. Bartsch D., Hahn S.A., Danichevski K.D., Ramaswamy A., Bastian D., Galehdari H., Barth P., Schmiegel W., Simon B., and Rothmund M. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene 18 (1999) 2367-2371
148. Johnson J.P. Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. Cancer Metastasis Rev. 10 (1991) 11-22
149. Kaiser U., Auerbach B., and Oldenburg M. The neural cell adhesion molecule NCAM in multiple myeloma. Leuk. Lymphoma 20 (1996) 389-395
150. Fogar P., Basso D., Pasquali C., De Paoli M., Sperti C., Roveroni G., Pedrazzoli S., and Plebani M. Neural cell adhesion molecule (N-CAM) in gastrointestinal neoplasias. Anticancer Res. 17 (1997) 1227-1230
151. Perl A.K., Dahl U., Wilgenbus P., Cremer H., Semb H., and Christofori G. Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic β tumor cells. Nat. Med. 5 (1999) 286-291
152. Seelentag W.K., Li W.P., Schmitz S.F., Metzger U., Aeberhard P., Heitz P.U., and Roth J. Prognostic value of beta 1,6-branched oligosaccharides in human colorectal carcinoma. Cancer Res. 58 (1998) 5559-55564
153. Li W.P., Komminoth P., Zuber C., Kloppel G., Heitz P.U., and Roth J. Can malignancy in insulinoma be predicted by the expression of patterns of beta 1,6 branching of aspargine-linked oligosaccharides and polysialic acid of the neural cell adhesion molecule?. Virchows Arch. 429 (1996) 197-204
154. Perl A.K., Wilgenbus P., Dahl U., Semb H., and Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392 (1998) 190-193
155. Marhaba R., and Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J. Mol. Histol. 35 (2004) 211-231
156. Komminoth P., Seelentag W.K., Saremaslani P., Heitz P.U., and Roth J. CD44 isoform expression in the diffuse neuroendocrine system. II Benign and malignant tumors. Histochem. Cell Biol. 106 (1996) 551-562
157. Imam H., Eriksson B., and Oberg K. Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumors. Ann. Oncol. 11 (2000) 295-300
158. Morrison H., Sherman L.S., Legg J., Banine F., Isacke C., Haipek C.A., Gutmann D.H., Ponta H., and Herrlich P. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 15 (2001) 968-980
159. Nowak M.A., Komarova N.L., Sengupta A., Jallepalli P.V., Shih I.M., Vogelstein B., and Lengauer C. The role of chromosomal instability in tumor initiation. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16226-16231
160. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
161. Draviam V.M., Xie S., and Sorger P.K. Chromosome segregation and genomic stability. Curr. Opin. Genet. Dev. 14 (2004) 120-125
162. Wild A., Langer P., Ramaswamy A., Chaloupka B., and Bartsch D.K. A novel insulinoma tumor suppressor gene locus on chromosome 22q with potential prognostic implications. J. Clin. Endocrinol. Metab. 86 (2001) 5782-5787
163. Heitz P.U., Kasper M., Kloppel G., Polak J.M., and Vaitukaitis J.L. Glycoprotein-hormone alpha-chain production by pancreatic endocrine tumors: a specific marker for malignancy. Immunocytochemical analysis of tumors of 155 patients. Cancer 51 (1983) 277-282
164. Bordi C., Pilato F.P., and D'adda T. Comparative study of seven neuroendocrine markers in pancreatic endocrine tumors. Virchows Arch., A Pathol. Anat. Histopathol. 413 (1988) 387-398
165. Graeme-Cook F., Bell D.A., Flotte T.J., Preffer F., Pastel-Levy C., Nardi G., and Compton C. Aneuploidy in pancreatic insulinomas does not predict malignancy. Cancer 66 (1990) 2365-2368
166. Ohike N., and Morohoshi T. Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation. Pathol. Int. 51 (2001) 770-777
167. Guo S.S., Wu X., Shimoide A.T., Wong J., and Sawicki M.P. Anomalous overexpression of p27(Kip1) in sporadic pancreatic endocrine tumors. J. Surg. Res. 96 (2001) 284-288
168. Rahman A., Maitra A., Ashfaq R., Yeo C.J., Cameron J.L., and Hansel D.E. Loss of p27 nuclear expression in a prognostically favorable subset of well-differentiated pancreatic endocrine neoplasms. Am. J. Clin. Pathol. 120 (2003) 685-690
169. Goto A., Niki T., Terado Y., Fukushima J., and Fukayama M. Prevalence of CD99 protein expression in pancreatic endocrine tumors (PETs). Histopathology 45 (2004) 384-392
170. Ali A., Serra S., Asa S.L., and Chetty R. The predictive value of CK19 and CD99 in pancreatic endocrine tumors. Am. J. Surg. Pathol. 30 (2006) 1588-1594
171. Kwaspen F.H.L., Smedts F.M.M., Broos A., Bulten H., Debie W.M.H., and Ramaekers F.C.S. Reproducable and highly sensitive detection of the broad spectrum epithelial marker keratin 19 in routine cancer diagnosis. Histopathology 31 (1997) 503-516
172. Bouwens L. Cytokeratins and cell differentiation in the pancreas. J. Pathol. 184 (1998) 234-239
173. Deshpande V., Fernandez-del Castillo C., Muzikansky A., Deshpande A., Zukerberg L., Warshaw A.L., and Lauwers G.Y. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am. J. Surg. Pathol. 28 (2004) 1145-1153
174. La Rosa S., Rigoli E., Uccella S., Novario R., and Capella C. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumors. Histopathology 50 (2007) 597-606
175. Albarello L., Capitanio V., Zerbi A., Di Carlo V., and Doglioni C. Cytokeratin 19 expression in pancreatic endocrine tumors. J. Pancreas 6 (2004) 514
176. Ward J.M., and Devor-Henneman D.E. Mouse models of human familial cancer syndromes. Toxicol. Pathol. 32 (2004) 90-98
177. Hanahan D. Heritable formation of pancreatic beta-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315 (1985) 115-122
178. Evers B.M., Ishizuha J., Townsend Jr. C.M., and Thompson J.C. The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann. N. Y. Acad. Sci. 733 (1994) 393-406
179. Iguchi H., Hayashi I., and Kono A. A somatostatin-secreting cell line established from a human pancreatic islet cell carcinoma (somatostatinoma): release experiment and immunohistochemical study. Cancer Res. 50 (1990) 3691-3693
180. Baroni M.G., Cavallo M.G., Mark M., Monetini L., Stoehrer B., and Pozzilli P. Beta-cell gene expression and functional characterisation of the human insulinoma cell line CM. J. Endocrinol. 161 (1999) 59-68
181. Gartner W., Koc F., Nabokikh A., Daneva T., Niederle B., Luger A., and Wagner L. Long-term in vitro growth of human insulin-secreting insulinoma cells. Neuroendocrinology 83 (2006) 123-130
182. Duran I., Salazar R., Casanovas O., Arrazubi V., Vilar E., Siu L.L., Yao J., and Tabernero J. New drug development in digestive neuroendocrine tumors. Ann. Oncol. (2007) (Epub ahead of print)